Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634666 | 0.87 | HDAC2 (0.48) | OPRD1OPRK1TACR1TSHRALOX15 | |
| SCHEMBL26633602 | 0.87 | GPR119 (0.52) | OPRD1OPRK1GPR119JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL5812318 | 0.86 | HDAC2 (0.47) | OPRD1OPRK1TACR1TSHRALOX15 | |
| SCHEMBL23660646 | 0.86 | NAMPT (0.58) | OPRD1OPRK1GPR119JAK2JAK1 | |
| SCHEMBL30017841 | 0.86 | NAMPT (0.58) | OPRD1OPRK1GPR119JAK2JAK1 | |
| SCHEMBL12203692 | 0.85 | OPRD1 (0.53) | OPRD1OPRK1TACR1STSGPR119 | |
| SCHEMBL2951728 | 0.85 | OPRD1 (0.53) | OPRD1OPRK1TACR1STSGPR119 | |
| SCHEMBL31302093 | 0.85 | OPRD1 (0.46) | OPRD1OPRK1TACR1STSGPR119 | |
| SCHEMBL8512562 | 0.85 | OPRD1 (0.53) | OPRD1OPRK1TACR1STSGPR119 | |
| SCHEMBL14902527 | 0.85 | OPRD1 (0.53) | OPRD1OPRK1TACR1STSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-114341124-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2023043836-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-3523302-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10144734-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1781623-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | OPRD1 4634/4885OPRK1 4212/4885TACR1 2802/4885 |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PTP4A1, PPP5C | OPRD1 4683/4885OPRK1 4378/4885TACR1 2762/4885 |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-10144734-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | OPRD1 3198/4885OPRK1 3176/4885TACR1 252/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OPRD1 2909/4885OPRK1 2369/4885TACR1 2730/4885 |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | OPRD1 3329/4885OPRK1 2748/4885TACR1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.